CollPlant Biotechnologies (NASDAQ:CLGN) Receives Buy Rating from D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of CollPlant Biotechnologies (NASDAQ:CLGN) in a research note released on Wednesday morning,Benzinga reports. D. Boral Capital currently has a $14.00 price objective on the stock.

Several other research analysts have also commented on the company. HC Wainwright restated a “buy” rating and set a $11.00 price target on shares of CollPlant Biotechnologies in a research report on Wednesday, August 21st. EF Hutton Acquisition Co. I upgraded CollPlant Biotechnologies to a “strong-buy” rating in a report on Monday, August 5th.

CollPlant Biotechnologies Stock Performance

Shares of CLGN stock opened at $4.21 on Wednesday. The firm has a market cap of $48.23 million, a P/E ratio of -2.76 and a beta of 0.44. The firm’s 50 day moving average price is $4.31 and its 200-day moving average price is $4.85. CollPlant Biotechnologies has a one year low of $3.31 and a one year high of $6.99.

Hedge Funds Weigh In On CollPlant Biotechnologies

Institutional investors have recently modified their holdings of the business. Benjamin Edwards Inc. purchased a new position in CollPlant Biotechnologies in the third quarter valued at $112,000. Villere ST Denis J & Co. LLC raised its position in CollPlant Biotechnologies by 24.4% in the 3rd quarter. Villere ST Denis J & Co. LLC now owns 484,867 shares of the company’s stock valued at $2,407,000 after purchasing an additional 95,000 shares in the last quarter. Finally, Pinnacle Associates Ltd. boosted its stake in shares of CollPlant Biotechnologies by 6.4% in the 2nd quarter. Pinnacle Associates Ltd. now owns 564,360 shares of the company’s stock valued at $2,805,000 after buying an additional 33,905 shares during the period. Institutional investors and hedge funds own 21.69% of the company’s stock.

CollPlant Biotechnologies Company Profile

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology.